Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics Worth Up to $2 Billion
On Jun. 3, 2026, Alnylam Pharmaceuticals, the leading RNAi therapeutics company, and Inceptive Nucleics, which builds foundation models…